ZYME vs XNCR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 12, 2026

ZYME

45.9
AI Score
VS
ZYME Wins

XNCR

34.0
AI Score

Investment Advisor Scores

ZYME

46score
Recommendation
HOLD

XNCR

34score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric ZYME XNCR Winner
Forward P/E 65.3595 68.0272 ZYME
PEG Ratio 0 0 Tie
Revenue Growth -90.6% 17.5% XNCR
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 45.9/100 34.0/100 ZYME
Profit Margin 0.0% -155.6% ZYME
Beta 1.00 1.00 Tie
AI Recommendation HOLD SELL ZYME

Relative Price Performance (Last 90 Days)

ZYME 1M: +24.0% · 3M: +14.2% XNCR 1M: +42.3% · 3M: +146.7%

Current Technical Phase

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 72

RSI (14): 71.6 · Price: $28.67

XNCR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (30.8% over 20 days), RSI 80

RSI (14): 80.2 · Price: $27.80

Fundamentals Snapshot

Metric ZYME XNCR
Market Cap
Forward P/E 24.4 -8.0
Trailing P/E
Revenue (TTM)
Revenue Growth -0.9% 0.2%
Gross Margin -2.5% -1.4%
Operating Margin -9.2% -0.7%
EPS -2.02 -2.16
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ZYME is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.